| FDA NEWS FDA approves smartphone blood-sugar monitor FDA approves GSK's Promacta for treatment of SAA |
 |
CVS stops selling tobacco, offers quit-smoking programs
USA TODAY - September 3, 2014
CVS Caremark plans to stop selling tobacco products in all of its stores starting Wednesday — a move health experts hope will be followed by other major drugstore chains.
Pharma Battles Hospitals Over Discount Pricing Program
Pharmaceutical Executive - September 3, 2014
Continued growth in a federal program that provides low-cost drugs to safety-net hospitals has sparked “trench warfare” over which medicines and providers are eligible for the deep discounts, and whether program expansion has undermined the original intent of the law.
Using Genomics to Follow the Path of Ebola
National Institutes of Health - September 2, 2014
Long before the current outbreak of Ebola Virus Disease (EVD) began in West Africa, NIH-funded scientists had begun collaborating with labs in Sierra Leone and Nigeria to analyze the genomes and develop diagnostic tests for the virus that caused Lassa fever, a deadly hemorrhagic disease related to EVD. But when the outbreak struck in February 2014, an international team led by NIH Director’s New Innovator Awardee Pardis Sabeti quickly switched gears to focus on Ebola.
Pharmacy’s battle for provider status reaches crescendo at state, federal level
Drug Store News - August 20, 2014
“All providers in the healthcare system should practice to the fullest extent allowed by their license.”
Programs Aim to Standardize Surgical Care for Children
Wall Street Journal - September 1, 2014
New System Classifies Pediatric Surgical Centers According to the Level of Care They Provide
Dosage of HIV Drug May Be Ineffective for Half of African-Americans
Infection Control Today - August 27, 2014
Many African-Americans may not be getting effective doses of the HIV drug maraviroc, a new study from Johns Hopkins suggests. The initial dosing studies, completed before the drug was licensed in 2007, included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body.
More dose escalation and cost with infliximab, compared with other TNF inhibitors in RA
Rheumatology News Digital Network - August 28, 2014
Only 2% of rheumatoid patients on etanercept underwent dose escalation, compared with 16% of patients on adalimumab and 64% of patients on infliximab, while annual costs for the first course of TNF inhibitor therapy were $13,100 for adalimumab, $13,500 for etanercept, and $16,900 for the intravenously-administered infliximab, without any significant differences in disease activity scores.
Powerful New Cancer Drugs Offer Hope—at Steep Cost
Wall Street Journal - September 3, 2014
The first of a promising new class of cancer drugs went on sale in Japan this week at an average annual cost of $143,000 a patient, a harbinger of hefty prices the new drugs are expected to command in the U.S. and Europe in coming months.
Study: Aspirin Might Work Instead of Warfarin for Deep Vein Clots
HealthDay News - August 26, 2014
Aspirin may offer an alternative for people who've had blood clots in the deep veins of the legs and can't tolerate long-term use of blood thinners, according to Australian researchers.
Heart Failure Drug Cuts Deaths, Hospitalizations by 20%
Associated Press - August 30, 2014
A new study reports one of the biggest potential advances against heart failure in more than a decade— a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20%.
Fears of addiction keep cancer patients from getting pain relief
Reuters - August 29, 2014
Fears of opioid abuse and addiction might be keeping patients with advanced cancer from getting enough pain medicine, researchers say.
Prescription for better stroke care: Prescription at discharge improves outcomes
ScienceDaily - August 27, 2014
Stroke patients are 70 percent more likely to continue taking their stroke prevention medications one year later if they have a prescription in hand when discharged, according to researchers. After having a stroke or minor stroke, the risk of having another stroke is greater. The risk of recurrence, however, can be reduced by more than 80 per cent by following stroke prevention strategies such as rehabilitation and taking medications.
Contact,
Kristin LaVitola
Marketing Director, PSG
Pharmaceutical Strategies Group (PSG)
Office: 972-244-8388
Email: KLavitola@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |